The neuroscience antibodies & assays market size has grown rapidly in recent years. It will grow from $5.03 billion in 2025 to $5.76 billion in 2026 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to rising prevalence of neurological disorders, expansion of neuroscience research funding, increased use of immunoassays in diagnostics, availability of advanced laboratory instruments, growth of academic neuroscience programs.
The neuroscience antibodies & assays market size is expected to see rapid growth in the next few years. It will grow to $9.83 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing investments in neurodegenerative disease research, rising demand for personalized neurology diagnostics, expansion of drug discovery programs, growing adoption of automated assay platforms, increasing focus on early disease detection. Major trends in the forecast period include increasing adoption of high-specificity antibody reagents, rising use of multiplex assay platforms, growing integration of automation in neuro research labs, expansion of biomarker-based neurological studies, enhanced focus on reproducibility and sensitivity.
The growing incidence of neurological disorders is anticipated to drive the expansion of the neuroscience antibodies and assays market in the coming years. Neurological disorders encompass conditions that affect the brain, spinal cord, and peripheral nerves, leading to impairments in cognitive, motor, or sensory functions. The rise in these conditions is primarily attributed to an aging global population, particularly in developed economies, where a larger proportion of elderly individuals has increased the prevalence of age-associated disorders such as Alzheimer’s disease and Parkinson’s disease. The escalating burden of neurological disorders is boosting demand for specialized antibodies and assays, as researchers and healthcare professionals increasingly rely on these tools to identify, analyze, and monitor disease-specific biomarkers and protein abnormalities. For example, in March 2023, data from the Alzheimer’s Association indicated that approximately 6.7 million Americans aged 65 years and above were living with Alzheimer’s dementia in 2023, a figure projected to reach 13.8 million by 2060. Consequently, the rising incidence of neurological disorders is supporting the growth of the neuroscience antibodies and assays market.
Leading companies operating in the neuroscience antibodies and assays space are increasingly concentrating on the development of advanced solutions, including bispecific in vivo-ready antibodies, to enable simultaneous targeting of multiple neurological pathways and achieve more accurate and effective research outcomes. Bispecific in vivo-ready antibodies are designed to bind two different targets at the same time and are optimized for use in live animal models, allowing researchers to influence multiple neurological mechanisms concurrently for more physiologically relevant studies. For instance, in October 2025, Bio X Cell LLC launched an expanded portfolio of bispecific antibodies and antibody-drug conjugates (ADCs) as part of a refreshed brand initiative aimed at supporting advanced preclinical neuroscience and translational research. These bispecific antibodies are capable of engaging two distinct antigens simultaneously, enabling the modulation of multiple signaling pathways or brain cell populations within a single experiment, unlike conventional monoclonal antibodies that act on a single target. Manufactured to high purity levels of at least 95% and with ultra-low endotoxin content of 0.5 EU/mg or less, these products are suitable for sensitive in vivo studies, organoid models, and organ-on-chip applications. The ADC offerings further integrate a functional antibody with a cytotoxic payload to selectively target specific neuronal or glial populations, providing enhanced experimental precision and flexibility.
In December 2023, Danaher Corporation, a United States-based life sciences and diagnostics company, completed the acquisition of Abcam plc for an undisclosed value. Through this transaction, Danaher sought to strengthen its portfolio of life science reagents and consumables, enhance its protein research tool capabilities for both research and diagnostic applications, accelerate growth across the life sciences ecosystem, and expand its global footprint in delivering integrated solutions to researchers and clinicians. Abcam plc is a United Kingdom-based biotechnology company recognized for supplying antibodies, reagents, assays, and related tools used in life science research.
Major companies operating in the neuroscience antibodies & assays market are Abcam plc, BioLegend Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Merck KGaA, Rockland Immunochemicals Inc., GenScript Biotech Corporation, Santa Cruz Biotechnology Inc., Wak-Chemie Medical GmbH, Epitope Diagnostics Inc., Agilent Technologies, Bio-Techne Corporation, Creative Diagnostics, Enzo Life Sciences Inc., Jackson ImmunoResearch Laboratories Inc., Novus Biologicals LLC, OriGene Technologies Inc., Proteintech Group Inc., R&D Systems Inc., RayBiotech Inc., StressMarq Biosciences Inc., Synaptic Systems GmbH, Tocris Bioscience, Alomone Labs Ltd., AnaSpec Inc., Antibodies.com, Antibody Solutions, Arbor Assays, Uscn Life Science Inc., Zymo Research Corp., AAT Bioquest Inc., Abbexa Ltd., ACROBiosystems Inc., Active Motif Inc., AdipoGen Life Sciences, Advanced Targeting Systems Inc., AgriSera AB.
North America was the largest region in the neuroscience antibodies & assays market in 2025. The regions covered in the neuroscience antibodies & assays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neuroscience antibodies & assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the neuroscience antibodies and assays market by increasing costs of imported reagents, assay kits, laboratory instruments, and analytical systems. Research institutes and pharmaceutical companies in North America and Europe are most affected due to reliance on imported consumables, while Asia-Pacific faces cost pressures on assay manufacturing. These tariffs are raising research expenses and extending procurement cycles. At the same time, they are encouraging domestic reagent production, regional supply chain development, and local manufacturing of assay components.
The neuroscience antibodies & assays market research report is one of a series of new reports that provides neuroscience antibodies & assays market statistics, including neuroscience antibodies & assays industry global market size, regional shares, competitors with a neuroscience antibodies & assays market share, detailed neuroscience antibodies & assays market segments, market trends and opportunities, and any further data you may need to thrive in the neuroscience antibodies & assays industry. This neuroscience antibodies & assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Neuroscience antibodies and assays play a crucial role in examining the development, systems, structure, function, disorders, and degeneration of the nervous system. Neuroscience, as a field, focuses on understanding the nervous system, its functioning, and disorders associated with it. Antibodies and assays, which are medical tests based on the interaction between antigenic epitopes and antibodies, find significant utility in neuroscience and the investigation of neurological disorders.
The primary categories of products in the neuroscience antibodies and assays market include consumables and instruments. Consumables, essential in numerous neurological studies and research experiments, comprise assay kits, reagents, and antibodies, facilitating quantitative and real-time live-cell analysis. Technologies employed in this domain encompass molecular diagnostics, clinical chemistry, immunoassays or immunochemistry, and other relevant technologies. Applications of neuroscience antibodies and assays span in vitro diagnostics, research, and drug discovery. The end users of these products are diverse, including hospitals and diagnostics centers, academic and research institutes, as well as pharmaceutical and biotechnology companies.
The neuroscience antibodies & assays market consists of sales of antibodies and assay kits and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The neuroscience antibodies & assays market size is expected to see rapid growth in the next few years. It will grow to $9.83 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing investments in neurodegenerative disease research, rising demand for personalized neurology diagnostics, expansion of drug discovery programs, growing adoption of automated assay platforms, increasing focus on early disease detection. Major trends in the forecast period include increasing adoption of high-specificity antibody reagents, rising use of multiplex assay platforms, growing integration of automation in neuro research labs, expansion of biomarker-based neurological studies, enhanced focus on reproducibility and sensitivity.
The growing incidence of neurological disorders is anticipated to drive the expansion of the neuroscience antibodies and assays market in the coming years. Neurological disorders encompass conditions that affect the brain, spinal cord, and peripheral nerves, leading to impairments in cognitive, motor, or sensory functions. The rise in these conditions is primarily attributed to an aging global population, particularly in developed economies, where a larger proportion of elderly individuals has increased the prevalence of age-associated disorders such as Alzheimer’s disease and Parkinson’s disease. The escalating burden of neurological disorders is boosting demand for specialized antibodies and assays, as researchers and healthcare professionals increasingly rely on these tools to identify, analyze, and monitor disease-specific biomarkers and protein abnormalities. For example, in March 2023, data from the Alzheimer’s Association indicated that approximately 6.7 million Americans aged 65 years and above were living with Alzheimer’s dementia in 2023, a figure projected to reach 13.8 million by 2060. Consequently, the rising incidence of neurological disorders is supporting the growth of the neuroscience antibodies and assays market.
Leading companies operating in the neuroscience antibodies and assays space are increasingly concentrating on the development of advanced solutions, including bispecific in vivo-ready antibodies, to enable simultaneous targeting of multiple neurological pathways and achieve more accurate and effective research outcomes. Bispecific in vivo-ready antibodies are designed to bind two different targets at the same time and are optimized for use in live animal models, allowing researchers to influence multiple neurological mechanisms concurrently for more physiologically relevant studies. For instance, in October 2025, Bio X Cell LLC launched an expanded portfolio of bispecific antibodies and antibody-drug conjugates (ADCs) as part of a refreshed brand initiative aimed at supporting advanced preclinical neuroscience and translational research. These bispecific antibodies are capable of engaging two distinct antigens simultaneously, enabling the modulation of multiple signaling pathways or brain cell populations within a single experiment, unlike conventional monoclonal antibodies that act on a single target. Manufactured to high purity levels of at least 95% and with ultra-low endotoxin content of 0.5 EU/mg or less, these products are suitable for sensitive in vivo studies, organoid models, and organ-on-chip applications. The ADC offerings further integrate a functional antibody with a cytotoxic payload to selectively target specific neuronal or glial populations, providing enhanced experimental precision and flexibility.
In December 2023, Danaher Corporation, a United States-based life sciences and diagnostics company, completed the acquisition of Abcam plc for an undisclosed value. Through this transaction, Danaher sought to strengthen its portfolio of life science reagents and consumables, enhance its protein research tool capabilities for both research and diagnostic applications, accelerate growth across the life sciences ecosystem, and expand its global footprint in delivering integrated solutions to researchers and clinicians. Abcam plc is a United Kingdom-based biotechnology company recognized for supplying antibodies, reagents, assays, and related tools used in life science research.
Major companies operating in the neuroscience antibodies & assays market are Abcam plc, BioLegend Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Merck KGaA, Rockland Immunochemicals Inc., GenScript Biotech Corporation, Santa Cruz Biotechnology Inc., Wak-Chemie Medical GmbH, Epitope Diagnostics Inc., Agilent Technologies, Bio-Techne Corporation, Creative Diagnostics, Enzo Life Sciences Inc., Jackson ImmunoResearch Laboratories Inc., Novus Biologicals LLC, OriGene Technologies Inc., Proteintech Group Inc., R&D Systems Inc., RayBiotech Inc., StressMarq Biosciences Inc., Synaptic Systems GmbH, Tocris Bioscience, Alomone Labs Ltd., AnaSpec Inc., Antibodies.com, Antibody Solutions, Arbor Assays, Uscn Life Science Inc., Zymo Research Corp., AAT Bioquest Inc., Abbexa Ltd., ACROBiosystems Inc., Active Motif Inc., AdipoGen Life Sciences, Advanced Targeting Systems Inc., AgriSera AB.
North America was the largest region in the neuroscience antibodies & assays market in 2025. The regions covered in the neuroscience antibodies & assays market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neuroscience antibodies & assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the neuroscience antibodies and assays market by increasing costs of imported reagents, assay kits, laboratory instruments, and analytical systems. Research institutes and pharmaceutical companies in North America and Europe are most affected due to reliance on imported consumables, while Asia-Pacific faces cost pressures on assay manufacturing. These tariffs are raising research expenses and extending procurement cycles. At the same time, they are encouraging domestic reagent production, regional supply chain development, and local manufacturing of assay components.
The neuroscience antibodies & assays market research report is one of a series of new reports that provides neuroscience antibodies & assays market statistics, including neuroscience antibodies & assays industry global market size, regional shares, competitors with a neuroscience antibodies & assays market share, detailed neuroscience antibodies & assays market segments, market trends and opportunities, and any further data you may need to thrive in the neuroscience antibodies & assays industry. This neuroscience antibodies & assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Neuroscience antibodies and assays play a crucial role in examining the development, systems, structure, function, disorders, and degeneration of the nervous system. Neuroscience, as a field, focuses on understanding the nervous system, its functioning, and disorders associated with it. Antibodies and assays, which are medical tests based on the interaction between antigenic epitopes and antibodies, find significant utility in neuroscience and the investigation of neurological disorders.
The primary categories of products in the neuroscience antibodies and assays market include consumables and instruments. Consumables, essential in numerous neurological studies and research experiments, comprise assay kits, reagents, and antibodies, facilitating quantitative and real-time live-cell analysis. Technologies employed in this domain encompass molecular diagnostics, clinical chemistry, immunoassays or immunochemistry, and other relevant technologies. Applications of neuroscience antibodies and assays span in vitro diagnostics, research, and drug discovery. The end users of these products are diverse, including hospitals and diagnostics centers, academic and research institutes, as well as pharmaceutical and biotechnology companies.
The neuroscience antibodies & assays market consists of sales of antibodies and assay kits and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Neuroscience Antibodies & Assays Market Characteristics
3. Neuroscience Antibodies & Assays Market Supply Chain Analysis
4. Global Neuroscience Antibodies & Assays Market Trends and Strategies
5. Neuroscience Antibodies & Assays Market Analysis of End Use Industries
7. Global Neuroscience Antibodies & Assays Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Neuroscience Antibodies & Assays Total Addressable Market (TAM) Analysis for the Market
9. Neuroscience Antibodies & Assays Market Segmentation
10. Neuroscience Antibodies & Assays Market Regional and Country Analysis
11. Asia-Pacific Neuroscience Antibodies & Assays Market
12. China Neuroscience Antibodies & Assays Market
13. India Neuroscience Antibodies & Assays Market
14. Japan Neuroscience Antibodies & Assays Market
15. Australia Neuroscience Antibodies & Assays Market
16. Indonesia Neuroscience Antibodies & Assays Market
17. South Korea Neuroscience Antibodies & Assays Market
18. Taiwan Neuroscience Antibodies & Assays Market
19. South East Asia Neuroscience Antibodies & Assays Market
20. Western Europe Neuroscience Antibodies & Assays Market
21. UK Neuroscience Antibodies & Assays Market
22. Germany Neuroscience Antibodies & Assays Market
23. France Neuroscience Antibodies & Assays Market
24. Italy Neuroscience Antibodies & Assays Market
25. Spain Neuroscience Antibodies & Assays Market
26. Eastern Europe Neuroscience Antibodies & Assays Market
27. Russia Neuroscience Antibodies & Assays Market
28. North America Neuroscience Antibodies & Assays Market
29. USA Neuroscience Antibodies & Assays Market
30. Canada Neuroscience Antibodies & Assays Market
31. South America Neuroscience Antibodies & Assays Market
32. Brazil Neuroscience Antibodies & Assays Market
33. Middle East Neuroscience Antibodies & Assays Market
34. Africa Neuroscience Antibodies & Assays Market
36. Neuroscience Antibodies & Assays Market Competitive Landscape and Company Profiles
37. Neuroscience Antibodies & Assays Market Other Major and Innovative Companies
40. Neuroscience Antibodies & Assays Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Neuroscience Antibodies & Assays Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses neuroscience antibodies & assays market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for neuroscience antibodies & assays? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neuroscience antibodies & assays market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Consumables; Instruments2) By Technology: Molecular Diagnostics; Immunoassays Or Immunochemistry; Other Technologies
3) By Application: In Vitro Diagnostics; Research; Drug Discovery
4) By End User: Hospitals And Diagnostics Centers; Academic And Research Institutes; Pharmaceutical And Biotechnology Companies
Subsegments:
1) By Consumables: Antibodies; Assay Kits2) By Instruments: Spectrophotometers; Microplate Readers; Flow Cytometers; Western Blotting Systems; Imaging Systems; Automated Workstations
Companies Mentioned: Abcam plc; BioLegend Inc.; Bio-Rad Laboratories Inc.; Cell Signaling Technology Inc.; F. Hoffmann-La Roche AG; Thermo Fisher Scientific; Merck KGaA; Rockland Immunochemicals Inc.; GenScript Biotech Corporation; Santa Cruz Biotechnology Inc.; Wak-Chemie Medical GmbH; Epitope Diagnostics Inc.; Agilent Technologies; Bio-Techne Corporation; Creative Diagnostics; Enzo Life Sciences Inc.; Jackson ImmunoResearch Laboratories Inc.; Novus Biologicals LLC; OriGene Technologies Inc.; Proteintech Group Inc.; R&D Systems Inc.; RayBiotech Inc.; StressMarq Biosciences Inc.; Synaptic Systems GmbH; Tocris Bioscience; Alomone Labs Ltd.; AnaSpec Inc.; Antibodies.com; Antibody Solutions; Arbor Assays; Uscn Life Science Inc.; Zymo Research Corp.; AAT Bioquest Inc.; Abbexa Ltd.; ACROBiosystems Inc.; Active Motif Inc.; AdipoGen Life Sciences; Advanced Targeting Systems Inc.; AgriSera AB
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Neuroscience Antibodies & Assays market report include:- Abcam plc
- BioLegend Inc.
- Bio-Rad Laboratories Inc.
- Cell Signaling Technology Inc.
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific
- Merck KGaA
- Rockland Immunochemicals Inc.
- GenScript Biotech Corporation
- Santa Cruz Biotechnology Inc.
- Wak-Chemie Medical GmbH
- Epitope Diagnostics Inc.
- Agilent Technologies
- Bio-Techne Corporation
- Creative Diagnostics
- Enzo Life Sciences Inc.
- Jackson ImmunoResearch Laboratories Inc.
- Novus Biologicals LLC
- OriGene Technologies Inc.
- Proteintech Group Inc.
- R&D Systems Inc.
- RayBiotech Inc.
- StressMarq Biosciences Inc.
- Synaptic Systems GmbH
- Tocris Bioscience
- Alomone Labs Ltd.
- AnaSpec Inc.
- Antibodies.com
- Antibody Solutions
- Arbor Assays
- Uscn Life Science Inc.
- Zymo Research Corp.
- AAT Bioquest Inc.
- Abbexa Ltd.
- ACROBiosystems Inc.
- Active Motif Inc.
- AdipoGen Life Sciences
- Advanced Targeting Systems Inc.
- AgriSera AB
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 5.76 Billion |
| Forecasted Market Value ( USD | $ 9.83 Billion |
| Compound Annual Growth Rate | 14.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 40 |
